Kainos Medicine, Inc. (KOSDAQ: 284620)
South Korea
· Delayed Price · Currency is KRW 3,975.00
-25.00 (-0.63%)
Nov 15, 2024, 9:00 AM KST
Kainos Medicine Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2019 | FY 2018 | FY 2017 | FY 2014 | FY 2013 | 2012 - 2009 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '20 Mar 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | 2012 - 2009 |
| Cash & Equivalents | - | - | - | - | 850.82 | 924.73 | Upgrade
|
| Short-Term Investments | - | - | - | - | - | 552.7 | Upgrade
|
| Cash & Short-Term Investments | - | - | - | - | 850.82 | 1,477 | Upgrade
|
| Cash Growth | - | - | - | - | -42.41% | -14.77% | Upgrade
|
| Other Receivables | - | - | - | - | 5.36 | 14.21 | Upgrade
|
| Receivables | - | - | - | - | 5.36 | 14.21 | Upgrade
|
| Prepaid Expenses | - | - | - | - | - | 14.24 | Upgrade
|
| Other Current Assets | - | - | - | - | 102.38 | 125.93 | Upgrade
|
| Total Current Assets | - | - | - | - | 958.56 | 1,632 | Upgrade
|
| Property, Plant & Equipment | - | - | - | - | 21.05 | 48.7 | Upgrade
|
| Long-Term Investments | - | - | - | - | 2.2 | 5.91 | Upgrade
|
| Other Intangible Assets | - | - | - | - | 373.63 | 385.06 | Upgrade
|
| Other Long-Term Assets | - | - | - | - | 69.13 | 130.24 | Upgrade
|
| Total Assets | - | - | - | - | 1,425 | 2,202 | Upgrade
|
| Accrued Expenses | - | - | - | - | 11.54 | 10.9 | Upgrade
|
| Current Unearned Revenue | - | - | - | - | 160.85 | 91.67 | Upgrade
|
| Other Current Liabilities | - | - | - | - | 217.78 | 210.15 | Upgrade
|
| Total Current Liabilities | - | - | - | - | 390.17 | 312.71 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | 240 | 360 | Upgrade
|
| Total Liabilities | - | - | - | - | 630.17 | 672.71 | Upgrade
|
| Common Stock | 1,080 | 1,080 | 1,080 | 180.2 | 4,393 | 3,815 | Upgrade
|
| Additional Paid-In Capital | 18,511 | 18,511 | 18,511 | 1,736 | 27,896 | 26,740 | Upgrade
|
| Retained Earnings | 242.83 | 223.24 | 63.08 | -7.41 | -32,527 | -30,459 | Upgrade
|
| Comprehensive Income & Other | - | - | - | - | 32.39 | 31.99 | Upgrade
|
| Total Common Equity | 19,835 | 19,815 | 19,655 | 1,909 | -205.6 | 129.01 | Upgrade
|
| Shareholders' Equity | 19,835 | 19,815 | 19,655 | 1,909 | 794.41 | 1,529 | Upgrade
|
| Total Liabilities & Equity | 19,835 | 19,815 | 19,655 | 1,909 | 1,425 | 2,202 | Upgrade
|
| Net Cash (Debt) | - | - | - | - | 850.82 | 1,477 | Upgrade
|
| Net Cash Growth | - | - | - | - | -42.41% | -14.77% | Upgrade
|
| Net Cash Per Share | - | - | - | - | 96.66 | 193.59 | Upgrade
|
| Filing Date Shares Outstanding | 5.4 | 5.4 | 5.4 | - | 8.8 | 7.63 | Upgrade
|
| Total Common Shares Outstanding | 5.4 | 5.4 | 5.4 | - | 8.8 | 7.63 | Upgrade
|
| Working Capital | - | - | - | - | 568.4 | 1,319 | Upgrade
|
| Book Value Per Share | 3672.38 | 3668.75 | 3639.10 | - | -23.36 | 16.91 | Upgrade
|
| Tangible Book Value | 19,835 | 19,815 | 19,655 | 1,909 | -579.23 | -256.05 | Upgrade
|
| Tangible Book Value Per Share | 3672.38 | 3668.75 | 3639.10 | - | -65.81 | -33.55 | Upgrade
|
| Machinery | - | - | - | - | 266.5 | 245.29 | Upgrade
|
| Leasehold Improvements | - | - | - | - | 1.8 | 93.68 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.